The promise of dynamic contrast-enhanced imaging in radiation therapy.
The promise of dynamic contrast-enhanced imaging in radiation therapy.
复制标题
DOI：
10.1016/j.semradonc.2010.11.001
复制
发表时间：
2011-04
影响因子：
3.5
通讯作者：
Cao, Yue
中科院分区：
文献类型：
--
作者：
Cao, Yue
动态对比增强（DCE）磁共振成像（MRI）和计算机断层扫描（CT）正在成为定量绘制肿瘤和正常器官中灌注、血管通透性、血容量和平均通过时间等血管参数空间分布的有价值的工具。DCE MRI/CT显示了某些癌症对化疗和放疗反应的预后和预测价值。DCE MRI/CT提供了早期评估肿瘤对放射治疗的反应的承诺，打开了一个窗口，用于基于早于形态学变化发生的功能改变自适应地优化放射治疗。DCE MRI/CT还显示了在正常器官和组织中绘制剂量反应图的潜力，用于评价个体对辐射的敏感性，为最大限度地减少辐射损伤风险提供了额外的机会。潜在地应用DCE MRI和CT来选择和描绘辐射增强靶点的证据正在增加。DCE MRI和CT作为肿瘤和正常器官放射治疗评估的生物标志物甚至替代终点的临床使用必须考虑技术验证问题，包括标准化，再现性，准确性和稳健性，以及对每个感兴趣的特定问题的灵敏度和特异性的临床验证。虽然有很大的希望，但迄今为止，DCE MRI和CT尚未被证明是任何肿瘤部位的任何前瞻性III期临床试验中放射治疗评估或治疗调整的替代终点。
Dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI) and computed tomography (CT) are emerging as valuable tools to quantitatively map the spatial distribution of vascular parameters such as perfusion, vascular permeability, blood volume, and mean transit time in tumors and normal organs. DCE MRI/CT have shown prognostic and predictive value for response of certain cancers to chemo and radiation therapy. DCE MRI/CT offer the promise of early assessment of tumor response to radiation therapy, opening a window for adaptively optimizing radiation therapy based upon functional alterations that occur earlier than morphological changes. DCE MRI/CT have also shown the potential of mapping dose-responses in normal organs and tissue for evaluation of individual sensitivity to radiation, providing additional opportunities to minimize risks of radiation injury. The evidence for potentially applying DCE MRI and CT for selection and delineation of radiation boost targets is growing. The clinical use of DCE MRI and CT as a biomarker or even a surrogate endpoint for radiation therapy assessment of tumor and normal organs must consider technical validation issues, including standardization, reproducibility, accuracy and robustness, as well as clinical validation of the sensitivity and specificity for each specific problem of interest. Although holding great promise, to date DCE MRI and CT have not been qualified as a surrogate endpoint for radiation therapy assessment or for treatment modification in any prospective phase III clinical trial for any tumor site.
登录
查看更多内容
影响因子：
3.8
作者：
Cao, Yue;Platt, Joel F.;Lawrence, Theodore S.
通讯作者：
Lawrence, Theodore S.
DOI：
10.1158/1078-0432.ccr-08-1420
发表时间：
2009-03-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Cao Y;Tsien CI;Sundgren PC;Nagesh V;Normolle D;Buchtel H;Junck L;Lawrence TS
通讯作者：
Lawrence TS
影响因子：
2.9
作者：
Galbraith, SM;Lodge, MA;Padhani, AR
通讯作者：
Padhani, AR
DOI：
10.1016/j.ijrobp.2007.05.078
发表时间：
2008-01-01
影响因子：
7
作者：
Cao, Yue;Pan, Charlie;Lawrence, Theodore S.
通讯作者：
Lawrence, Theodore S.
影响因子：
4.4
作者：
Cheng, Hai-Ling Margaret
通讯作者：
Cheng, Hai-Ling Margaret